Form D · Biotechnology
Regenevida, Inc.
St. Paul, MN · CIK 0001736337
Offering snapshot reported Sep 6, 2018 · SEC filing
- Reported sold
- $7.36K Offering amount: $23.6M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 20, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 6, 2018 | Initial | $7,358 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-320800
Total Offering Amount includes $7,358 equity offering, plus warrants to purchase up to 2,943,042 shares of common stock at $8.00 per share, which may never be exercised.
Source: Form D, filed Sep 6, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John F. Cameron | Executive |
| Scott Fahrenkrug | Director, Executive |
| Walter Low | Executive |
| Justin Zenanko | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1246 University Avenue West Suite 301
St. Paul, MN, 55104
St. Paul, MN, 55104